Completed
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
NCT00322608
- Conditions
- Cancer, Hemic and Lymphatic Diseases, Immune System Diseases, +6 more
- Locations
-
- Barbara Ann Karmanos Cancer Institute/Wayne State University Detroit, Michigan, United States
- Institute for Drug Development San Antonio, Texas, United States
- Northwest Medical Specialties Tacoma, Washington, United States